is a protein that interacts with angiotensin II type 1 (AT1) receptors and facilitates increased AT1 receptor surface expression in vitro. In the present study, we assessed the tissue localization and regulation of Arap1 in vivo. Arap1 was found in various mouse organs, with the highest expression in the heart, kidney, aorta, and adrenal gland. Renal Arap1 protein was restricted to the vasculature and to glomerular mesangial cells and was absent from tubular epithelia. A similar localization was found in human kidneys. To test the hypothesis that angiotensin II may control renal Arap1 expression, mice were subjected to various conditions to alter the activity of the renin-angiotensin system. A high-salt diet (4% NaCl, 7 days) upregulated Arap1 expression in mice by 47% compared with controls (0.6% NaCl, P ϭ 0.03). Renal artery stenosis (7 days) or water restriction (48 h) suppressed Arap1 levels compared with controls (Ϫ64 and Ϫ62% in the clipped and contralateral kidney, respectively; and Ϫ50% after water restriction, P Ͻ 0.01). Angiotensin II infusion (2 g·kg Ϫ1 ·min Ϫ1 , 7 days) reduced Arap1 mRNA levels compared with vehicle by 29% (P Ͻ 0.01), whereas AT1 antagonism (losartan, 30 mg·kg Ϫ1 ·day Ϫ1 , 7 days) enhanced Arap1 mRNA expression by 52% (P Ͻ 0.01); changes in mRNA were paralleled by Arap1 protein abundance. Experiments with hydralazine and epithelial nitric oxide synthaseϪ/Ϫ mice further suggested that Arap1 expression changed in parallel with angiotensin II, rather than with blood pressure per se. Similar to in vivo, Arap1 mRNA and protein were suppressed by angiotensin II in a time-and dose-dependent manner in cultured mesangial cells. In summary, Arap1 is highly expressed in the renal vasculature, and its expression is suppressed by angiotensin II. Thus Arap1 may serve as a local modulator of vascular AT1 receptor function in vivo.
levels target AT 1 receptors in all accessible tissues, mechanisms have evolved to allow for local regulation of angiotensin II sensitivity. These mechanisms include local changes in AT 1 receptor expression, receptor desensitization, and internalization (4) . Furthermore, AT 1 receptor-associated proteins have emerged as possible additional local modulators of AT 1 receptor function. Several proteins that interact with AT 1 receptors have been described (8, 12, 16, 32, 33) . For example, the angiotensin receptor-associated protein Atrap, which is highly expressed in the proximal tubule of the kidney, acts as a negative regulator of AT 1 receptors and facilitates AT 1 receptor internalization (11, 12, 21) . Consequently, Atrap-deficient mice have increased arterial blood pressure and blood volume (24) . Guo et al. (16) discovered another AT 1 -associated protein, named Arap1 (angiotensin receptor-associated protein 1), which binds to the C-terminal domain of the AT 1 receptor. Unlike Atrap, Arap1 was shown to catalyze the recycling of the AT 1 receptor to the cell membrane in vitro (16) . The in vivo relevance of Arap1 was addressed using transgenic mouse lines that overexpressed Arap1 in the proximal tubule under the control of the KAP promoter (15) . Arap1 transgenic mice developed salt-sensitive and angiotensin II-dependent hypertension, which was accompanied by marked kidney hypertrophy (15) . These data suggest that Arap1 enhances AT 1 -dependent signaling in the kidney. Although expression of Arap1 has been demonstrated in the kidney of the rat and mouse (16) , its exact localization in rodent and human kidney is unknown.
In vitro responses to angiotensin II, e.g., vascular contraction, often display desensitization, and chronic angiotensin II infusion in vivo can only maintain elevated blood pressure through AT 1 receptors in kidney but not in heart and vessels (9) . This differential sensitivity of the AT 1 receptor could be related to angiotensin-associated proteins.
In this study, we investigated the localization of Arap1 in the kidney of mice and humans and hypothesized that expression of Arap1 is regulated by angiotensin II.
Renal Arap1 expression in mice and humans was predominantly localized in the vasculature. High oral salt intake increased Arap1 levels, whereas conditions such as salt restriction, unilateral renal artery stenosis, and water restriction suppressed Arap1 levels compared with controls. Similarly, angiotensin II infusion decreased renal Arap1 expression, whereas AT 1 antagonism enhanced it. In vitro experiments revealed that angiotensin II-dependent suppression of Arap1 expression was mediated by AT 1 receptors. These data indicate that Arap1 may serve as a local modulator of renal vascular AT 1 receptor function.
Our data suggest that Arap1 may contribute to adaptive changes in local AT 1 receptor surface expression.
METHODS
Determination of Arap1 mRNA expression. Total RNA was isolated from various organs of the mouse using TRIzol reagent (Invitrogen). To localize Arap1 expression to specific zones of the kidney, mouse and human kidney specimens were microdissected and divided into the cortex, outer medulla outer stripe (OMOS), outer medulla inner stripe (OMIS) and inner medulla (IM). cDNA was obtained by reverse transcription (M-MLV-RT, Invitrogen), and real-time PCR was performed for Arap1, ␤-actin, and GAPDH using the Light-Cycler system (Roche, Mannheim, Germany). Arap1 mRNA expression data were normalized to ␤-actin or GAPDH mRNA expression. The following oligonucleotide primers were used: mouse Arap1 sense 5=-ccagaaagcgagtactataagctgc-3=; mouse Arap1 antisense 5=-cttagtggaaggtgttggggttgg-3=; rat Arap1 sense 5=-ccagaaagcgagtactataagctgc-3=; rat Arap1 antisense 5=-cttaatggaaagtgttggggttgg -3=; human Arap1 sense 5=-gtgactcctttacatggcacaac-3=; human Arap1 antisense 5=-cttagtggaaggtgttggggttcgg-3=; mouse AT 1 receptor sense 5=-agagttaagggccattttgcttt-3=; mouse AT1 receptor antisense 5=-tcaccagatcaagtgcattttga-3=; mouse and human ␤-actin sense 5=-ccgccctaggcaccagggtg-3=; mouse and human ␤-actin antisense 5=-ggctggggtgttgaaggtctcaaa-3=; mouse and human GAPDH-sense 5=-ttcattgacctcaactacat-3=; and mouse and human GAPDH-antisense 5=-gaggggccatccacagtctt-3=.
Measurement of Arap1 protein levels by immunoblotting. Western blotting was performed according to standard protocols. Total protein from mouse organs was obtained by homogenization in RIPA buffer (137 mM NaCl, 3 mM KCl, 25 mM Tris·HCl, pH 7.5, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing 0.1 M PMSF. After centrifugation, the supernatant was stored at Ϫ80°C until further use. For the protein preparation from cultured mesangial cells, cells were incubated in RIPA buffer containing 0.1 M PMSF for 1 h at 4°C after washing with PBS. The cell suspensions were cleared from cell debris by two centrifugation steps at 4°C. The supernatant was stored at Ϫ20°C. Protein concentrations were determined by the bicinchoninic acid method (BCA Protein assay Kit, Pierce) with BSA as a standard. In total, 200 g of total mouse kidney protein and 25 g of rat mesangial cell protein were loaded onto an SDS-polyacrylamide gels and separated by electrophoresis. After blotting onto a nitrocellulose membrane (Transfer-Blot Transfer Medium, Bio-Rad), nonspecific binding sites were blocked by incubation in TBS buffer containing skim milk. Arap1 protein was detected by incubating with antiArap1 antibody (1:500, R&D Systems) for 2 h followed by incubation with a secondary anti-goat antibody conjugated to horseradish peroxidase (1:2,000, donkey anti-goat IgG, Santa Cruz Biotechnology). Using ECL Western Blotting substrate (Pierce), Arap1 protein was visualized on X-ray film and signals densities were quantified using Bio1D software (Vilber Lourmat).
Immunohistochemistry. Immunohistochemistry was performed on paraffin sections of mouse and human kidneys. Anesthetized mice were perfused with 3% paraformaldehyde through the abdominal aorta. Organs were removed and embedded in paraffin. Sections 5 m in width were dehydrated and unmasked by heat treatment in sodium citrate buffer (pH 6). Rabbit anti-Arap1 IgGs (HPA040933, Atlas Antibodies; ARP54835_P050, Aviva Systems Biology) were diluted 1:200 and 1:1,000, respectively, in 10% horse serum/1% BSA/PBS and used together with goat anti-desmin IgG (1:100, sc-7559, Santa Cruz Biotechnology), mouse anti-␣-actin IgG (1:200, 1144, Immunotech), goat anti-CD31 IgG (1:100, AF 3628, R&D Systems), chicken anti-renin IgG (1:400, Davids Biotechnology), and goat anti-aquaporin-2 IgG (1:200, sc-9882, Santa Cruz Biotechnology), respectively. After incubation with secondary antibodies (Cy2-, Cy5-, TRITC-conjugated anti-goat, anti-rabbit, anti-chicken IgG, 1:400, Dianova), the sections were analyzed using an Axiovert 200M microscope (Zeiss). Staining without the primary antibody served as a negative control.
Human specimens. Human kidney tissue was derived from male patients with renal cancer who underwent radical unilateral nephrectomy. All patients gave their informed written consent before participating in the study and had not received chemotherapy or radiation before nephrectomy. The patients were between 50 and 75 yr of age. Animals. For all experiments, male C57BL/6 mice were used. Animals used in the study were between 8 and 10 wk of age. All animal experiments were performed according to the National Insti- tutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the local authorities. In one set of experiments, male endothelial nitric oxide synthase (eNOS)Ϫ/Ϫ and wild-type mice were used (5) . eNOSϪ/Ϫ and wild-type mice were 10 wk of age.
Animal experiments. Various experimental maneuvers were created to assess the regulation of Arap1 expression during changes in renin-angiotensin system (RAS) activity.
For changes in oral salt intake, a group of 6 mice received a high [4% NaCl (wt/wt)-or low-salt diet 0.02% NaCl (wt/wt), Ssniff Spezialdiäten, Soest, Germany] for 7 days, while a control group (n ϭ 6) obtained a standard chow [0.6% NaCl (w/w)].
For water restriction, mice were kept for 48 h without access to water. A control group had free access to tap water (n ϭ 6 each).
For unilateral renal artery stenosis, the two-kidney-one-clip (2K1C) model of renovascular hypertension was used to induce unilateral renal artery stenosis. Mice were anesthetized with sevoflurane, the left kidney was exposed, and the renal artery was dissected from the renal vein and the surrounding tissue (n ϭ 6). A silver clip (0.11-mm inner diameter) was placed around the renal artery. The same surgical maneuver was performed in sham-operated mice (n ϭ 6); however, no clip was applied (30) . Kidneys were harvested after 7 days. To ensure appropriate clip placement, arterial blood pressure was determined by tail-cuff manometry, as described previously (25) .
For chronic infusion of angiotensin II, mice were infused with angiotensin II for 7 days via osmotic minipumps (model 1002, Alzet). Minipumps were loaded with angiotensin II dissolved in 300 mM NaCl and 1 mM acetic acid (2 g·min Ϫ1 ·kg angiotensin II Ϫ1 , SigmaAldrich). Pumps were implanted subcutaneously under sevoflurane anesthesia (n ϭ 10). A control group received osmotic minipumps filled with vehicle (n ϭ 10). Again, the function of the osmotic minipump was controlled by the determination of arterial blood pressure using tail-cuff manometry.
For angiotensin II receptor antagonism, mice received the AT 1 receptor antagonist losartan (Sigma-Aldrich) dissolved in their drinking water for 7 days (30 mg·kg Ϫ1 ·day Ϫ1 , n ϭ 6). A control group had free access to tap water (n ϭ 6).
For hydralazine administration, mice received hydralazine (SigmaAldrich) dissolved in the drinking water for 7 days (20 mg·kg Ϫ1 ·day Ϫ1 , n ϭ 5). A control group had free access to tap water (n ϭ 5).
At the end of all experiments, the mice were euthanized, and the kidneys were frozen in liquid nitrogen and stored at Ϫ80°C until further processing.
In vitro experiments. To assess the mechanisms regulating Arap1 expression, studies were performed in cultured rat glomerular mesangial cells (gift from Dr. Eberhardt, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany). This cell line expresses both Arap1 and the angiotensin receptors AT 1 and AT2. The cells were grown as described previously (27) . In brief, rat glomerular mesangial cells were cultured in RPMI 1640 (PAN Biotech) supplemented with 10% FCS, penicillin-streptomycin (100 U/ml, 100 g/ml, Biochrom), and 0.66 U/ml Insulin (Sigma-Aldrich) at 37°C and 5% CO 2. One day before the experiments, FCS was reduced to 0.5% and penicillinstreptomycin was omitted from the medium. To address the effect of angiotensin II on Arap1 mRNA expression, angiotensin II was added to the wells in final concentrations of 0, 10 Ϫ7 , 10 Ϫ6 , 10 Ϫ5 and 10 Ϫ4 mol/l. After various incubation times, cells were washed with PBS, suspended in TRIzol reagent, and stored at Ϫ80°C until further use. In an additional set of experiments, the AT 1 receptor antagonist losartan or the AT2 antagonist PD123319 was added 45 min before treatment with angiotensin II (10 Ϫ5 mol/l), and the cells were harvested after 20 h. In further experiments, protein kinase C was activated by PMA (Sigma-Aldrich). Unless otherwise stated, six wells of cells were investigated for each experimental condition.
Statistics. Data are expressed as means Ϯ SE. Statistical comparisons were made by Student's t-test or by ANOVA with Bonferroni post hoc tests when necessary.
RESULTS

Localization of Arap1 expression in mice and humans.
A multiple-tissue expression analysis of Arap1 in the mouse was performed using quantitative RT-PCR. Arap1 was found in various organs of the mouse with the following pattern of expression levels: heart Ͼ kidney Ͼ aorta Ͼ adrenal gland Ϸ liver Ϸ lung Ϸ testis Ϸ spleen Ϸ skeletal muscle Ͼ brain Ϸ intestine (Fig. 1, n ϭ 5 ). Arap1 mRNA expression paralleled respective protein levels, with the greatest amount of Arap1 in the heart (not shown). To assess the distribution pattern of Arap1 in different zones of the kidney, Arap1 mRNA levels were quantified for the cortex, OMOS and OMIS, and IM. Arap1 mRNA expression in the mouse kidney was characterized by a corticomedullary gradient, with cortical expression levels exceeding those of the OMOS, OMIS, and IM by 59 Ϯ 4, 40 Ϯ 10, and 130 Ϯ 7%, respectively (Fig. 2, n ϭ 5) . Immunohistochemistry with two antibodies targeting different epitopes of Arap1 revealed that Arap1 protein in the mouse kidney was localized primarily in the vasculature, as determined by costaining with anti-smooth muscle ␣-actin and anti-SM22 antibodies (Fig. 3, A-D) . In contrast to vascular smooth muscle cells, there was no Arap1 expression in the vascular endothelium, as determined by costaining with an anti-CD31 antibody (Fig. 3, I and J). Arap1 was found in both large arteries and small resistance vessels, including the afferent arterioles. Arap1 protein was absent from renin-positive juxtaglomerular (JG) cells (Fig. 3, E and F) . In addition, we found consistent Arap1 staining of glomeruli colocalizing with the mesangial cell marker desmin whereas Arap1 was absent from podocin-positive podocytes (not shown) and CD31-positive glomerular capillaries (Fig. 3J ). In the renal medulla, Arap1 expression was found in the vasa recta as determined by costaining with anti-smooth muscle ␣-actin, whereas no Arap1 could be detected in aquaporin-2-positive medullary collecting ducts (Fig. 4) . Similarly, no Arap1 immunostaining was observed in any other segment of the tubular system of the kidney.
In the human kidney, Arap1 mRNA could be detected in all kidney zones, with a similar distribution pattern as is found in the mouse kidney (not shown). Arap1 protein in the human kidney, as detected by immunostaining, was expressed in the vasculature, with the most intense staining in the renal cortex (Fig. 5) . Similar to the mouse, vessels of the renal cortex of various sizes including the afferent arterioles expressed Arap1 (Fig. 5A) . Unlike in mice, there was no apparent Arap1 staining in mesangial cells of the human kidney. Arap1-positive vessels were also present in the medulla of the human kidney (Fig. 5C) .
Regulation of renal Arap1 expression in vivo. Because Arap1 may serve as a local modulator for the RAS by promoting AT 1 receptor surface expression, we evaluated whether and how Arap1 expression changed with different levels of angiotensin II plasma concentrations.
Variations in oral salt intake are classic modulators of RAS activity. Thus mice received an experimental diet with high [4% NaCl (wt/wt)], standard [0.6% NaCl (wt/wt)], or low [0.02% NaCl (wt/wt)] salt content for 1 wk, and renal Arap1 expression was determined afterward. As shown in Fig. 6 , a high-salt diet led to upregulation of Arap1 mRNA expression in mouse kidneys by 47 Ϯ 14% compared with controls (P ϭ 0.03). Conversely, a low-salt diet decreased Arap1 expression by 27 Ϯ 5% compared with a standard diet, although this difference did not reach statistical significance (P ϭ 0.07). For AT 1 receptor mRNA expression, we found no significant changes in abundance during the various dietary regimens (1.27 Ϯ 0.22, 1.18 Ϯ 0.15, and 1.05 Ϯ 0.23 rU for the high-, standard-, and low-salt diet, respectively; n ϭ 5).
Arap1 expression was also examined during water restriction, a condition accompanied by marked activation of the RAS. Expression of Arap1 mRNA decreased significantly after 48 h of water restriction, averaging 75 Ϯ 3%, 47 Ϯ 5%, and 28 Ϯ 4% of controls (free access to tap water) in the cortex, outer medulla and IM, respectively (n ϭ 6, P Ͻ 0.01) (Fig. 7) . Similar to Arap1 mRNA, Arap1 protein in the total kidney was significantly reduced by 46 Ϯ 12% after water restriction compared with controls (P Ͻ 0.05, n ϭ 6) (Fig. 7) .
In addition to modulating Arap1 expression, water restriction also influenced AT 1 receptor abundance. After 48 h of water restriction, renal AT 1 receptor mRNA abundance in water-restricted mice increased by 35 Ϯ 17% compared with controls (n ϭ 9, P ϭ 0.001). Changes in AT 1 mRNA abundance were paralleled by protein levels, which increased by 28 Ϯ 9%, as determined by immunoblotting.
Unilateral renal stenosis (2K1C, 7 days) was used in the next experiment as a model of hemodynamic activation of the RAS. At the end of the experiment, arterial blood pressure on the 2K1C animals had increased to 179 Ϯ 8 mmHg whereas blood pressure in the sham-operated mice averaged 122 Ϯ 5 mmHg (tail-cuff measurements, P Ͻ 0.01). Compared with shamoperated animals, renal artery stenosis resulted in downregulation of Arap1 mRNA expression by 64 Ϯ 6 and 62 Ϯ 2% in both the clipped and contralateral kidney, respectively (P Ͻ 0.001 vs. control) (Fig. 8) .
As both water restriction and renal artery stenosis result in increased levels of circulating angiotensin II, we also examined the direct effect of angiotensin II on renal Arap1 expression. Mice were chronically infused with angiotensin II via osmotic minipumps (2 g·kg Ϫ1 ·min Ϫ1 angiotensin II, 7 days). Angiotensin II infusion induced marked hypertension with arterial blood pressure levels averaging 158 Ϯ 2 vs. 116 Ϯ 2 mmHg in Fig. 9 . Expression of Arap1 in zones of the kidney after chronic angiotensin II infusion for 7 days (2 g·kg Ϫ1 ·min
Ϫ1
, n ϭ 10; A) and in the total kidney after 7 days of AT1 receptor antagonism (losartan, 30 mg·kg
, n ϭ 6; B). Values are means Ϯ SE expressed as relative units normalized to ␤-actin (n ϭ 10 each). Insets: Arap1 protein abundance in total kidneys after angiotensin II infusion and losartan, respectively.
vehicle-infused mice (P Ͻ 0.01). Compared with vehicleinfused mice, chronic angiotensin II infusion reduced Arap1 mRNA expression by 29 Ϯ 1.4 and 24 Ϯ 8% in the cortex and in the renal medulla (n ϭ 10, P Ͻ 0.001 and P ϭ 0.003), respectively (Fig. 8A) . Changes in Arap1 mRNA levels were accompanied by changes in total kidney Arap1 protein (Fig. 9A, inset) .
In contrast to suppression of Arap1 expression by angiotensin II infusion, AT 1 receptor antagonism by losartan (30 mg·kg Ϫ1 ·day Ϫ1 for 7 days; n ϭ 6) resulted in an increase in Arap1 mRNA averaging 152 Ϯ 15% of controls (P Ͻ 0.01) (Fig. 9B ) and which was accompanied by a marked induction of Arap1 protein abundance (Fig. 9B, inset) .
In parallel with Arap1, renal cortical AT 1 receptor mRNA abundance was decreased during angiotensin II infusion (Ϫ18 Ϯ 2% compared with controls, n ϭ 6) (P ϭ 0.01), whereas losartan upregulated AT 1 receptor levels without reaching levels of significance (n ϭ 6; P ϭ 0.14). Similarly, AT 1 protein tended to be reduced or increased during angiotensin II infusion or losartan administration, respectively (not shown).
To assess whether Arap1 expression is directly modulated by angiotensin II or rather by changes in arterial blood pressure, mice were given the vasodilator agent hydralazine (20 mg·kg Ϫ1 ·day Ϫ1 for 7 days in the drinking water) to reduce blood pressure and increase angiotensin II levels (6, 18) . Hydralazine reduced Arap1 mRNA expression by 28 Ϯ 6% compared with vehicle-infused mice (n ϭ 5, P ϭ 0.01) (Fig. 10A ). To further address a possible correlation between blood pressure and Arap1 expression, Arap1 expression was determined in a model of chronic hypertension. For this purpose, renal Arap1 mRNA was measured in eNOS-deficient mice and wild-type controls. In the eNOSϪ/Ϫ strain used in this study, marked hypertension is accompanied by virtually normal plasma renin concentration (5) . Arap1 expression in the kidneys of eNOSϪ/Ϫ mice averaged 0.92 Ϯ 0.15 rU, not significantly different from wild-type mice (1.10 Ϯ 0.19 rU, n ϭ 5, P ϭ 0.22) (Fig. 10B) .
To determine whether the regulation of Arap1 is tissue specific, Arap1 mRNA in the heart, aorta, and adrenal gland was determined after angiotensin II infusion. In contrast to the kidney, Arap1 in the heart and aorta was unchanged during angiotensin II infusion, whereas it was increased in the adrenal gland (1.26 Ϯ 0.2 rU vs. 0.68 Ϯ 0.1 rU in controls; P ϭ 0.01; not shown).
In summary, our in vivo experiments suggest that the expression of Arap1 in the kidney is dependent on the activity of the RAS and that the effect of angiotensin II on Arap1 is inhibitory.
Regulation of Arap1 expression: in vitro studies. To address the mechanisms underlying the regulation of Arap1 expression in vivo, we performed additional in vitro studies. As shown in Fig. 11 , angiotensin II led to a dose-dependent suppression of Arap1 expression in cultured mesangial cells averaging 71 Ϯ 4, 68 Ϯ 2, 44 Ϯ 2, and 25 Ϯ 2% of control after incubation for 16 h with 10 Ϫ7 , 10 Ϫ6 , 10 Ϫ5 , and 10 Ϫ4 mmol/l angiotensin, respectively (P Ͻ 0.001 for all angiotensin II concentrations). Maximal angiotensin II-dependent suppression of Arap1 mRNA levels was reached after 8 h of incubation (Fig. 10) . Similar to in vivo conditions, downregulation of Arap1 mRNA expression was followed by declining Arap1 protein levels as determined by Western blotting (Fig. 11, inset) . Downregulation of Arap1 was accompanied by a minor reduction in AT 1 receptor expression, which was largely independent of the concentration of angiotensin II, averaging 67 Ϯ 8, 80 Ϯ 9, 77 Ϯ 6, and 59 Ϯ 13% of controls for 10 Ϫ7 , 10 Ϫ6 , 10 Ϫ5 , and 10 Ϫ4 mmol/l angiotensin II (P Ͻ 0.05 for 10 Ϫ7 and 10 Ϫ4 mmol/l angiotensin II; n ϭ 6; not shown).
To determine the identity of the receptor involved in angiotensin II-dependent downregulation of Arap1 expression, we evaluated the effect of the AT 1 receptor antagonist losartan on Arap1 mRNA expression in cultured mesangial cells treated with angiotensin II. Pretreatment of mesangial cells with losartan (10 Ϫ4 mol/l) virtually abolished the effect of angiotensin II (10 Ϫ5 mol/l, 20 h) on Arap1 expression, resulting in a decrease in Arap1 mRNA expression to 96 Ϯ 4% of controls (P ϭ 0.13), whereas angiotensin II in the absence of losartan downregulated Arap1 expression to 65 Ϯ 4% of controls (P ϭ 0.001) (Fig. 12) . In contrast to AT 1 antagonism, blockade of AT2 receptors by PD123319 (10 Ϫ4 mol/l) did not alter the suppression of Arap1 expression by angiotensin II (Fig. 12) . AT 1 receptor-dependent regulation of Arap1 expression was mimicked by the PKC activator PMA. As shown in Fig. 13 , PMA (10 Ϫ5 and 10 Ϫ7 mmol/l) suppressed Arap1 mRNA expression to 46 Ϯ 8 and 52 Ϯ 5% of controls, respectively, which were similar to the effects of angiotensin II (10 Ϫ5 mmol/l) (P Ͻ 0.001). Data obtained from these in vitro experiments suggest that Arap1 expression is suppressed by angiotensin II and that this effect is mediated by AT 1 receptors.
DISCUSSION
Local changes in receptor expression, receptor internalization/membrane trafficking, and receptor-associated proteins are potential strategies to locally regulate the effects of the RAS. For the AT 1 receptor, accessory proteins that increase or decrease the surface expression of the AT 1 receptor and consequently locally modulate angiotensin II-mediated signaling have been described (8, 12, 16, 32, 33) .
We evaluated the localization and regulation of the AT 1 receptor-associated protein Arap1 in the kidney. Based on in vitro findings, Arap1 acts as a positive regulatory protein of AT 1 receptor function (16) . Thus Arap1 catalyzes the trafficking of the AT 1 receptor to the cell surface, which will increase baseline AT 1 surface expression and resensitize the cell after angiotensin II exposure (16) . Arap1 in the mouse was expressed in various organs, with particularly high expression levels in the heart and kidney. This finding is in accordance with previous observations in the rat indicating that Arap1 was expressed predominantly in the heart, kidney, and lung (16) . In the mouse kidney, Arap1 expression was found throughout the entire vasculature. A closer inspection of the vessels revealed that Arap1 staining was most intense in vascular smooth muscle cells, the site of the highest AT 1 receptor density in the kidney (14, 17, 23, 26) . Although Arap1 was found along virtually the entire renal vasculature, the renin-secreting JG cells of the afferent arteriole lacked Arap1, as determined by costaining with an anti-renin antibody. AT 1 receptors on JG cells mediate a direct inhibitory feedback loop on renin secretion (4). Thus the absence of Arap1 from JG cells may preserve the direct feedback loop of angiotensin II on renin secretion. In addition to the renal vasculature, Arap1 was also expressed in mesangial cells of the mouse. Mesangial cells highly express AT 1 receptors, and angiotensin II was shown to be involved in mesangial cell growth and secretion of extracellular matrix proteins, including collagens and fibronectin (1, 26) .
Our localization study was performed with two independent antibodies targeting different regions of the Arap1 protein. We are confident that these antibodies had decent specificity, as both antibodies independently detected a virtually identical localization pattern.
In the human kidney, Arap1 was found in vessels of the cortex and the medulla. The distribution pattern of Arap1 in the kidney was highly comparable between mice and humans, suggesting a similar functional relevance in both species. In contrast to mice, Arap1 expression in mesangial cells of the human kidney was at the detection limit, which could be due to lower overall expression levels of Arap1 in human compared with mouse kidney or due to the different tissue fixation procedures.
We did not detect any Arap1 protein in the tubular system of the kidney. At the moment, we cannot rule out that there is some minor tubular Arap1 expression that is below the detection limit of our antibodies; however, compared with the abundant expression of Arap1 in the renal vessels, the relevance of Arap1 for modulating the function of tubular AT 1 receptors is presumably limited.
In view of the regulation of AT 1 receptor surface expression by Arap1 in vitro, we next evaluated Arap1 levels during changes in RAS activity. Changes in Arap1 expression would constitute a measure for local adaptations of AT 1 receptor density in response to fluctuating systemic angiotensin II levels.
Oral salt intake is a classic determinant of RAS activity, with a salt-restricted diet stimulating and a high-salt diet suppressing renin secretion (4). Renal Arap1 expression was dependent on oral salt intake, although the suppression of Arap1 expression during a low-salt diet did not reach statistical significance. It should be noted in this context, however, that the stimulation of renin secretion in response to a low-salt diet in the mouse is usually limited, in particular compared with what is observed in situations like water restriction or renal hypoperfusion (4). Consequently, water restriction resulted in a markedly more pronounced downregulation of Arap1 levels compared with a low-salt diet.
Similar to water restriction, renal hypoperfusion results in augmented systemic angiotensin II levels (4) . Although this mechanism appears to be a reasonable measure to ensure constant arterial blood pressure under normal conditions, it also triggers the development of renovascular hypertension when renal perfusion pressure falls below normal due to renal artery stenosis. During experimental renal artery stenosis, Arap1 expression was downregulated to a similar degree in both the clipped and the contralateral kidney. Because perfusion pressure is presumably low in the clipped kidney and high in the contralateral kidney, it appears unlikely that renal perfusion pressure is a major determinant of Arap1 expression. This assumption is further supported by experiments using the vasodilator agent hydralazine. Hydralazine was shown to decrease arterial blood pressure and to stimulate renin secretion (6, 18) . In contrast to losartan treatment, Arap1 expression was slightly reduced in hydralazine-treated mice, suggesting that angiotensin II levels rather than blood pressure determined Arap1 expression. In line with these findings, renal Arap1 expression of eNOS-deficient mice, used as a model of chronic renin-independent hypertension (5), did not differ from wildtype mice.
These data indicate that changes in blood pressure per se most likely do not constitute a modulator of Arap1 in the kidney. According to the situation of renovascular hypertension, these data rather suggest that Arap1 is regulated by a factor that impinges on both kidneys similarly, such as angiotensin II.
In accordance with this hypothesis, angiotensin II infusion markedly reduced the abundance of renal Arap1 whereas AT 1 receptor antagonism stimulated Arap1 expression. Interestingly, the suppression of Arap1 expression was more pronounced during renal artery stenosis than during angiotensin II infusion. Although we did not determine angiotensin II concentrations in the plasma of angiotensin II-infused mice, we believe that arterial blood pressure may serve as an indirect measure of angiotensin II levels in the circulation. Because blood pressure in angiotensin II-infused mice was significantly lower compared with 2K1C mice, we assume that angiotensin II levels may have also been lower, which could account for the differences in Arap1 expression.
A direct inhibitory effect of angiotensin II on renal Arap1 expression was further suggested by in vitro experiments using a rat mesangial cell line. We found a dose-dependent suppression of Arap1 during exposure to angiotensin II; this effect appeared to be mediated by AT 1 receptors, as it could be blocked by AT 1 antagonism whereas AT2 blockade had no effect. Furthermore, AT 1 receptor activation by angiotensin II could be mimicked by activation of protein kinase C, a classic intracellular signaling pathway of the AT 1 receptor (22) . As Arap1 mRNA and protein expression were regulated in parallel under all experimental conditions, it appears likely that Arap1 abundance is primarily under transcriptional control.
Expression of AT 1 receptors and renal angiotensin II binding during changes in the activity of the RAS have been addressed in several studies. Some studies report that the overall expression of renal AT 1 receptors and angiotensin II binding capacity are reduced during a salt-restricted diet (28, 29) , whereas other studies showed that renal AT 1 receptors are upregulated during low oral salt intake (13, 36) . No changes in AT 1 receptor expression were found in our experiments for the renal cortex and medulla during variations in oral salt intake. These inconsistent results might be related to the fact that renal vascular and tubular AT 1 receptor expression is regulated inversely during changes in oral salt intake, which may limit net changes in receptor abundance (7, 28) . For chronic angiotensin II infusion, no change in total renal AT 1 receptor expression was reported, whereas radio-labeled angiotensin II binding was reduced (31) . According to our data, reduced expression of Arap1 during angiotensin II infusion may contribute to this apparent reduction in AT 1 receptor surface expression.
AT 1 receptor expression in our settings of angiotensin II infusion was slightly reduced in the cortex but unchanged in the medulla of the kidney. Congruent with these results, a downregulation of glomerular AT 1 receptors during angiotensin II infusion has been shown for the rat (19) .
In contrast to the renal vasculature, no Arap1 expression was found in tubular epithelia; however, the tubular system, and particularly the proximal tubule (the main site of tubular AT 1 receptor expression) (20) , expresses another angiotensin receptor-associated protein called Atrap (12) . Unlike Arap1, Atrap has been shown to facilitate the internalization of the AT 1 receptor and, consequently, may act as a negative local modulator of the AT 1 receptor (2, 11, 21) . Similar to Arap1, Atrap is downregulated under conditions of elevated angiotensin II levels (34, 35) . As a consequence, when the kidney is exposed to increased angiotensin II, reduced expression of both vascular Arap1 and tubular Atrap would desensitize the renal vasculature and concomitantly sensitize the proximal tubule for AT 1 receptor-dependent effects. In this context, recent studies showed a crucial role of renal AT 1 receptors for sustained angiotensin II-dependent hypertension (9, 10) . Jointly, Arap1 and Atrap therefore may facilitate angiotensin II-dependent tubular reabsorption and preserve glomerular filtration.
Our data suggest that downregulation of vascular Arap1 by angiotensin II might be kidney specific, because expression in the heart and aorta was unchanged, and even increased in the adrenal gland. Enhanced Arap1 abundance in the adrenal gland during angiotensin II infusion may contribute to long-term preservation of angiotensin II-dependent aldosterone release (4) . Further studies are necessary to assess the functional relevance of Arap1 for AT 1 signaling.
In summary, Arap1 is expressed in the renal vasculature of mice and humans. In vivo and in vitro data suggest that renal Arap1 expression is suppressed by AT 1 receptor activation. Thus Arap1 may serve as a local modulator of vascular AT 1 receptor function and may contribute to adaptations of the renal vasculature in response to increased levels of circulating angiotensin II.
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